Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
KRTX

KRTX - Karuna Therapeutics Inc Stock Price, Fair Value and News

329.83USD Market Closed

Market Summary

KRTX
USD329.83
Market Closed

KRTX Stock Price

View Fullscreen

KRTX RSI Chart

KRTX Valuation

Market Cap

12.6B

Price/Earnings (Trailing)

-29.05

Price/Sales (Trailing)

247.43

EV/EBITDA

-28.78

Price/Free Cashflow

-32.41

KRTX Price/Sales (Trailing)

KRTX Profitability

EBT Margin

-850.37%

Return on Equity

-34.58%

Return on Assets

-32.46%

Free Cashflow Yield

-3.09%

KRTX Fundamentals

KRTX Revenue

Revenue (TTM)

50.9M

Rev. Growth (Yr)

336.46%

Rev. Growth (Qtr)

2.14%

KRTX Earnings

Earnings (TTM)

-433.7M

Earnings Growth (Yr)

-49.35%

Earnings Growth (Qtr)

4.45%

Breaking Down KRTX Revenue

Last 7 days

3.1%

Last 30 days

2.8%

Last 90 days

50.1%

Trailing 12 Months

74.2%

How does KRTX drawdown profile look like?

KRTX Financial Health

Current Ratio

19.31

KRTX Investor Care

Shares Dilution (1Y)

10.67%

Diluted EPS (TTM)

-11.72

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202321.7M37.9M50.9M0
202230.4M23.8M17.2M10.6M
20212.1M1.4M19.2M37.0M
20203.5M4.1M4.0M3.3M
20190002.5M
20180000

Tracking the Latest Insider Buys and Sells of Karuna Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 18, 2024
meury william
back to issuer
-9,695,070
330
-29,379
president and ceo
Mar 18, 2024
paul steven m
back to issuer
-3,496,680
330
-10,596
-
Mar 18, 2024
paul steven m
back to issuer
-10,000,300
330
-30,304
-
Mar 18, 2024
torres denice
back to issuer
-326,700
330
-990
-
Mar 18, 2024
healy james
back to issuer
-11,051,700
330
-33,490
-
Mar 18, 2024
paul steven m
back to issuer
-11,181,100
330
-33,882
-
Mar 18, 2024
jonas jeffrey m
back to issuer
-326,700
330
-990
-
Mar 18, 2024
healy james
back to issuer
-225,390
330
-683
-
Mar 18, 2024
healy james
back to issuer
-2,648,250
330
-8,025
-
Mar 18, 2024
paul steven m
back to issuer
-11,839,400
330
-35,877
-

1–10 of 50

Which funds bought or sold KRTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 01, 2024
Legal & General Group Plc
sold off
-100
-10,393,900
-
-%
Jun 11, 2024
EverSource Wealth Advisors, LLC
sold off
-100
-27,853
-
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
sold off
-100
-6,326,000
-
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
sold off
-100
-165,218,000
-
-%
May 24, 2024
Cetera Investment Advisers
sold off
-100
-328,221
-
-%
May 20, 2024
Virtu Financial LLC
sold off
-100
-4,138,000
-
-%
May 16, 2024
COMERICA BANK
sold off
-100
-154,716
-
-%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-1,093,860
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
sold off
-100
-10,898,700
-
-%
May 15, 2024
Westchester Capital Management, LLC
sold off
-100
-32,020,100
-
-%

1–10 of 39

Are Funds Buying or Selling KRTX?

Are funds buying KRTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own KRTX
No. of Funds

Unveiling Karuna Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
t. rowe price investment management, inc.
7.2%
2,709,629
SC 13G
Feb 14, 2024
price t rowe associates inc /md/
5.2%
1,963,957
SC 13G/A
Feb 13, 2024
vanguard group inc
8.55%
3,224,786
SC 13G/A
Feb 12, 2024
fmr llc
-
0
SC 13G/A
Feb 12, 2024
capital international investors
1.2%
448,866
SC 13G/A
Feb 09, 2024
capital international investors
11.4%
4,314,384
SC 13G/A
Jan 31, 2024
blackrock inc.
5.3%
2,015,374
SC 13G
Jan 10, 2024
fmr llc
-
0
SC 13G/A
Jul 07, 2023
blackrock inc.
4.97%
1,864,318
SC 13G/A
Jun 21, 2023
sofinnova venture partners x, l.p.
3.7%
1,372,441
SC 13D/A

Peers (Alternatives to Karuna Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Karuna Therapeutics Inc News

Latest updates
TipRanks4 months ago
Investor's Business Daily7 months ago

Karuna Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q12018Q4
Revenue-100.0%-16,952,00016,597,00011,345,0006,026,0003,884,000490,000394,000298,000202,000106,000143,000441,000688,000779,0001,397,0001,092,000858,000115,000-
Operating Expenses-4.9%129,586,000136,218,000119,907,000109,720,00090,314,00081,075,00070,330,00058,594,00065,155,00051,168,00034,531,00029,963,00024,407,00019,529,00017,825,00010,055,0008,866,0009,896,00011,573,0008,146,000
  S&GA Expenses46.9%47,394,00032,266,00027,417,00024,253,00024,310,00019,125,00017,843,00014,788,00020,063,00012,393,00010,384,0009,777,0008,823,0006,944,0007,006,0005,635,0003,874,0004,103,0004,606,0001,426,000
  R&D Expenses-20.9%82,192,000103,952,00092,490,00085,467,00066,004,00061,950,00052,487,00043,806,00045,092,00038,775,00024,147,00020,186,00015,584,00012,585,00010,819,0004,420,0004,992,0005,793,0006,967,0006,720,000
EBITDA Margin-9.6%-8.47-7.73-9.29-14.40-25.74-13.15-8.43-5.62-3.88-7.28-77.99---------
Income Taxes-----890,000-528,000-6,000---43,000-------
Earnings Before Taxes5.0%-113,154,000-119,119,000-103,163,000-97,574,000-75,322,000-76,963,000-64,415,000-58,218,000-27,954,000-50,932,000-34,416,000-30,497,000-23,966,000-18,841,000-17,046,000-8,658,000-7,774,000-9,038,000-12,005,000-8,327,000
EBT Margin-9.6%-8.50-7.76-9.33-14.45-25.85-13.22-8.47-5.65-3.89-7.29-78.17---------
Net Income4.4%-113,824,000-119,119,000-103,163,000-97,574,000-76,212,000-76,963,000-64,943,000-58,218,000-27,960,000-50,932,000-34,416,000-30,497,000-24,009,000-18,841,000-17,046,000-8,658,000-7,774,000-9,038,000-12,005,000-8,327,000
Net Income Margin-9.5%-8.52-7.78-9.35-14.52-25.98-13.25-8.49-5.65-3.89-7.30-78.20---------
Free Cashflow-1.1%-111,839,000-110,626,000-64,975,000-101,314,000-79,047,000-60,120,000-39,951,000-49,803,000-7,767,000-45,325,000-29,632,000-21,226,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-3.5%1,3361,3851,4721,5161,1631,22843447452854057759334836437839039316479.0048.0016.00
  Current Assets-3.7%1,3151,3651,4521,5081,1551,22042446551752956759034536137538739316479.00-16.00
    Cash Equivalents0.7%18618426456324862813617620725234635453.0045.0013419120954.0010.00-9.00
  Net PPE15.0%5.005.004.004.003.003.003.003.003.003.002.000.000.000.000.000.000.000.000.00-0.00
Liabilities30.6%82.0063.0053.0028.0037.0044.0028.0021.0026.0022.0017.008.009.007.006.005.003.002.002.003.004.00
  Current Liabilities39.1%68.0049.0039.0025.0034.0041.0024.0016.0020.0016.0010.007.007.005.004.003.003.002.002.00-1.00
Shareholder's Equity-5.1%1,2541,3221,4201,4881,1261,184405454502518560585339357372385390163---
  Retained Earnings-12.9%-997-884-764-661-564-488-411-346-287-259-208-174-144-120-101-84.17-75.51-67.74-58.70--31.55
  Additional Paid-In Capital2.1%2,2562,2092,1882,1521,6941,67681980279077876975948347747246846523012.00-2.00
Shares Outstanding0.9%38.0038.0038.0037.0034.0031.0030.0030.0029.0030.0029.00----------
Float---5,873---2,921---3,027---2,231---197--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-0.9%-111-110-64.16-100-78.76-59.95-39.50-49.80-7.00-43.81-28.89-21.18-22.94-22.78-15.79-8.34-6.82-8.42-9.57-6.11-6.86
  Share Based Compensation24.6%23.0018.0018.0016.0013.0012.0012.0011.008.008.007.006.004.004.003.002.001.002.007.003.000.00
Cashflow From Investing226.5%92.0028.00-253-27.49-306-292-5.5518.00-42.02-50.3719.0051.0030.00-66.83-42.05-10.43-72.62-42.18-64.525.00-
Cashflow From Financing647.2%20.003.0018.004425.008445.001.004.001.002.002712.001.001.001.0023494.000.0077.003.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

KRTX Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
License and other revenue$ 654$ 10,637$ 36,964
Operating expenses:   
Research and development364,101224,247128,200
General and administrative131,33076,06652,617
Total operating expenses495,431300,313180,817
Loss from operations(494,777)(289,676)(143,853)
Other income, net:   
Interest income61,17914,178502
Sublease income588580254
Impairment loss on right-of-use assets00(702)
Total other income, net61,76714,75854
Net loss before income taxes(433,010)(274,918)(143,799)
Income tax provision(670)(1,418)(6)
Net loss attributable to common stockholders$ (433,680)$ (276,336)$ (143,805)
Net loss per share, basic$ (11.73)$ (8.74)$ (4.94)
Net loss per share, diluted$ (11.73)$ (8.74)$ (4.94)
Weighted average common shares outstanding used in computing net loss per share, basic36,959,04931,629,01329,138,915
Weighted average common shares outstanding used in computing net loss per share, diluted36,959,04931,629,01329,138,915

KRTX Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 185,823$ 248,329
Investment securities, available-for-sale1,074,957875,715
Short-term investments, other2,0330
Accounts receivable057
Prepaid expenses39,99329,106
Other current assets12,5071,562
Total current assets1,315,3131,154,769
Restricted cash0261
Right-of-use lease assets - operating, net15,0904,674
Property and equipment, net5,4243,201
Other non-current assets382429
Total assets1,336,2091,163,334
Current liabilities:  
Accounts payable6,7832,379
Accrued expenses41,60929,285
Current portion of operating lease liability2,8432,282
Other current liabilities16,8940
Total current liabilities68,12933,946
Operating lease liability, net of current portion13,8453,046
Other non-current liabilities0104
Total liabilities81,97437,096
Commitments and Contingencies (Note 10)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and 0 shares outstanding as of December 31, 2023 and 202200
Common stock, $0.0001 par value; 150,000,000 shares authorized as of December 31, 2023 and 2022; 38,091,829 and 34,473,905 shares issued as of December 31, 2023 and 2022; 38,077,525 and 34,473,905 shares outstanding as of December 31, 2023 and 2022, respectively43
Additional paid-in capital2,256,4311,693,732
Accumulated deficit(997,887)(564,207)
Accumulated other comprehensive (loss) income211(3,290)
Treasury stock at cost, 14,304 and 0 shares as of December 31, 2023 and 2022, respectively(4,524)0
Total stockholders’ equity1,254,2351,126,238
Total liabilities and stockholders’ equity$ 1,336,209$ 1,163,334
KRTX
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEkarunatx.com
 INDUSTRYBiotechnology
 EMPLOYEES210

Karuna Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Karuna Therapeutics Inc? What does KRTX stand for in stocks?

KRTX is the stock ticker symbol of Karuna Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Karuna Therapeutics Inc (KRTX)?

As of Mon Mar 18 2024, market cap of Karuna Therapeutics Inc is 12.6 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KRTX stock?

You can check KRTX's fair value in chart for subscribers.

What is the fair value of KRTX stock?

You can check KRTX's fair value in chart for subscribers. The fair value of Karuna Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Karuna Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Karuna Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether KRTX is over valued or under valued. Whether Karuna Therapeutics Inc is cheap or expensive depends on the assumptions which impact Karuna Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KRTX.

What is Karuna Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Mar 18 2024, KRTX's PE ratio (Price to Earnings) is -29.05 and Price to Sales (PS) ratio is 247.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KRTX PE ratio will change depending on the future growth rate expectations of investors.